Genomed Inc (NYSE:GMED): Institutional Investor Sentiment Up to 1.18

Globus Medical, Inc. (NYSE:GMED) Logo

Sentiment for Genomed Inc (NYSE:GMED)

Genomed Inc (NYSE:GMED) institutional sentiment increased to 1.18 in Q2 2018. Its up 0.12, from 1.06 in 2018Q1. The ratio has increased, as 127 funds increased or opened new stock positions, while 108 reduced and sold holdings in Genomed Inc. The funds in our partner’s database now possess: 59.66 million shares, up from 58.48 million shares in 2018Q1. Also, the number of funds holding Genomed Inc in their top 10 stock positions increased from 4 to 5 for an increase of 1. Sold All: 29 Reduced: 79 Increased: 80 New Position: 47.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.50 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 31.91 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

The stock decreased 0.72% or $0.33 during the last trading session, reaching $45.72. About 32,974 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 72.10% since December 6, 2017 and is uptrending. It has outperformed by 56.48% the S&P500.

Analysts await Globus Medical, Inc. (NYSE:GMED) to report earnings on February, 20. They expect $0.40 earnings per share, up 5.26 % or $0.02 from last year’s $0.38 per share. GMED’s profit will be $39.38 million for 28.58 P/E if the $0.40 EPS becomes a reality. After $0.39 actual earnings per share reported by Globus Medical, Inc. for the previous quarter, Wall Street now forecasts 2.56 % EPS growth.

Paradigm Capital Management Inc Ny holds 2.99% of its portfolio in Globus Medical, Inc. for 735,500 shares. Godshalk Welsh Capital Management Inc. owns 55,088 shares or 2.91% of their US portfolio. Moreover, Pura Vida Investments Llc has 2.89% invested in the company for 67,500 shares. The Illinois-based Oak Ridge Investments Llc has invested 2.36% in the stock. Van Berkom & Associates Inc., a Quebec – Canada-based fund reported 1.26 million shares.

Globus Medical, Inc. (NYSE:GMED) Ratings Coverage

Ratings analysis reveals 33% of Globus Medical’s analysts are positive. Out of 3 Wall Street analysts rating Globus Medical, 1 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $55 while the high is $64. The stock’s average target of $58 is 26.86% above today’s ($45.72) share price. GMED was included in 4 notes of analysts from June 27, 2018. Morgan Stanley maintained it with “Overweight” rating and $60 target in Thursday, August 2 report. Morgan Stanley maintained Globus Medical, Inc. (NYSE:GMED) rating on Tuesday, September 25. Morgan Stanley has “Overweight” rating and $64 target. The stock of Globus Medical, Inc. (NYSE:GMED) has “Sell” rating given on Wednesday, June 27 by Bank of America.

More notable recent Globus Medical, Inc. (NYSE:GMED) news were published by: Seekingalpha.com which released: “Globus Medical acquires Nemaris – Seeking Alpha” on September 13, 2018, also Globenewswire.com with their article: “Globus Medical Enters Trauma Market NYSE:GMED – GlobeNewswire” published on March 06, 2018, Seekingalpha.com published: “Globus Medical Is Gaining Share In Its Mainstay Market – Seeking Alpha” on June 01, 2018. More interesting news about Globus Medical, Inc. (NYSE:GMED) were released by: Seekingalpha.com and their article: “Globus Medical beats by $0.07, beats on revenue – Seeking Alpha” published on November 08, 2018 as well as Globenewswire.com‘s news article titled: “Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio – GlobeNewswire” with publication date: July 03, 2018.

Globus Medical, Inc. (NYSE:GMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.